Skip to content

Application of cyclopropofol combined with alfentanil in catheter ablation of atrial fibrillation

Application of cyclopropofol combined with alfentanil in catheter ablation of atrial fibrillation

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095447
Enrollment
Unknown
Registered
2025-01-07
Start date
2024-05-26
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Catheter ablation of atrial fibrillation

Interventions

CP group:Cyclopropofol 0.2mg/kg+ alfentanil 3ug/kg was used for induction, followed by continuous pumping of cyclopropofol 1mg/kg/h until the end of surgery
P group:Induction was performed with propofol 1mg/kg+ alfentanil 3ug/kg, followed by propofol 4mg/kg/h continuous pump infusion until the end of surgery

Sponsors

Heze Municipal Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
38 Years to 58 Years

Inclusion criteria

Inclusion criteria: (1) for patients with symptomatic paroxysmal atrial fibrillation, persistent atrial fibrillation, or recurrent atrial fibrillation refractory to or intolerant of class I or class III antiarrhythmic drugs (all assessed by professional cardiologists, patients with radiofrequency ablation indications); (2) patients undergoing radiofrequency ablation for the first time (3) age of 18-65 years old (4) ASA grade I-II (5) BMI< 35 kg/m^2

Exclusion criteria

Exclusion criteria: (1) patients with recent repeated use of narcotic analgesics and opioid tolerance (2) myocardial infarction, ventricular dysfunction, coronary artery dysfunction; Complicated with serious bradyarrhythmias, such as sick sinus syndrome, III degree atrioventricular block (3) Severe pulmonary disease, severe anemia or thrombocytopenia, untreated hyperthyroidism, and severe hepatic and renal insufficiency (4) patients with vertigo and headache (5) patients with central nervous system (CNS) diseases, CNS stimulant drugs or respiratory defects; Patients with brain injury and increased intracranial pressure (6) drinking history within one week (7) patients with a history of mental disorders and epilepsy (8) patients allergic to study drugs and anticoagulant drugs (9) unable to communicate effectively with patients

Design outcomes

Primary

MeasureTime frame
Invasive blood pressure;Heart rate;Oxygen saturation of the pulse;BIS index;

Secondary

MeasureTime frame
The dose of alfentanil was added during the operation;Time of awakening after operation;

Countries

China

Contacts

Public ContactWenyu Zhao

No. 2888 Caozhou Road, Mudan District, Heze City

550323848@qq.com+86 199 6301 6150

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026